NCT02438696 - Relative Bioavailability of Two Newly Developed Tablet Formulations (TF2 and iFF)Compared to BI 1060469 TF1 Formulation, Following Oral Administration (Low and High Dose)in Healthy Female Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions

Healthy

Interventions

DRUG

BI 1060469, iFF, Test

DRUG

BI 1060469, iFF, Test

DRUG

BI 1060469, TF1, Reference

DRUG

BI 1060469, TF2, Test

DRUG

BI 1060469, TF2, Test

DRUG

BI 1060469, iFF, Test

DRUG

BI 1060469, TF1, Reference

DRUG

BI 1060469, iFF, Test

DRUG

BI 1060469, iFF, Test

DRUG

BI 1060469, TF1, Reference

DRUG

BI 1060469, TF2, Test

DRUG

BI 1060469, TF1, Reference

DRUG

BI 1060469, TF1, Reference

DRUG

BI 1060469, TF2, Test

DRUG

BI 1060469, TF2, Test

DRUG

BI 1060469, iFF, Test

DRUG

BI 1060469, TF2, Test

DRUG

BI 1060469, TF1, Reference

Trial Locations (1)

Unknown

1333.4.1 Boehringer Ingelheim Investigational Site, Biberach